Reviewing the therapeutic potential of Myricetin in diabetes and neurodegeneration

Myricetin, a flavonoid found in a variety of fruits, vegetables, and plants, has emerged as a prospective therapy candidate for diabetes and neurodegeneration due to its broad-spectrum pharmacological properties. This review examines myricetin's therapeutic potential in diabetes and neurodegenerative illnesses, focussing on its diverse modes of action. Myricetin has been demonstrated to reduce insulin resistance and β-cell dysfunction, which are significant elements in the pathogenesis of diabetes. Myricetin reduces oxidative stress, increasing insulin sensitivity and β-cell survival, potentially enhancing glycaemic management. Furthermore, its anti-inflammatory qualities may assist to reduce chronic low-grade inflammation, which is a hallmark of diabetes progression. Furthermore, myricetin has been demonstrated to inhibit ROS generation, hence decreasing neuroinflammatory responses that worsen neuronal injury. Diabetes and neurodegeneration share common mechanisms such as insulin resistance, oxidative stress, and inflammation, which has been well documented. Myricetin's ability to target these shared pathways makes it a promising therapeutic option for treating both diseases concurrently. The flavonoid's ability to regulate key molecular players in both diabetes and neurodegeneration highlights its potential as a combined therapeutic agent for these two chronic diseases.